Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
In a recent transaction filed with the Securities and Exchange Commission, Amy Beth VanDuyn, Senior Vice President of Human Resources at Phreesia, Inc. (NYSE:PHR), reported selling shares of the company's common stock. According to InvestingPro analysis, Phreesia currently shows signs of undervaluation, with a GREAT financial health score and positive growth expectations. The sales, which occurred on April 8, 2025, were conducted as part of the company's mandatory sell-to-cover policy to cover tax withholding obligations related to restricted stock units.
VanDuyn disposed of a total of 1,695 shares across two transactions. The first transaction involved the sale of 1,036 shares at a weighted average price of $23.4568, while the second transaction saw the sale of 659 shares at a weighted average price of $24.475. The total value of these transactions amounted to approximately $40,430. Following these sales, VanDuyn retains direct ownership of 130,444 shares of Phreesia.
In other recent news, Phreesia Inc . has seen several analyst firms weigh in on its financial outlook and stock performance. Jefferies raised its price target for Phreesia from $28 to $32, maintaining a Buy rating based on the company's fourth-quarter earnings and management's commentary. They highlighted Phreesia's operational leverage and strategic focus on Network Solutions as key growth drivers. Similarly, KeyBanc Capital Markets reiterated an Overweight rating with a $30 price target, noting significant margin improvement and top-line growth, particularly in the Network Solutions sector. Their analysis suggests a positive outlook for Phreesia's adjusted EBITDA margins and revenue growth in the coming years.
Raymond (NSE:RYMD) James also maintained an Outperform rating with a $30 price target, focusing on Phreesia's shift towards a free cash flow-oriented narrative. This strategic approach is expected to enhance earnings conversion into cash flow, supporting the valuation. DA Davidson echoed a positive sentiment, reiterating a Buy rating and setting a $36 price target. They emphasized Phreesia's performance in the U.S. healthcare services sector and considered the stock undervalued compared to its peers. These recent developments reflect a broad consensus among analysts about Phreesia's potential for growth and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.